关注并星标CPHI制药在线日前,北京康辰药业股份有限公司(简称:康辰药业)1类新药KC1086片在国内获得临床试验默示许可,拟用于晚期复发或转移性实体瘤。KC1086是康辰药业完全自主研发的一款具有全新结构的强效、高选择性赖氨酸乙酰转移酶6(KAT6)的小分子抑制剂。临床前研究显示:在ER+/HER2-的乳腺癌药效模型中,同等剂量水平下KC1086对肿瘤生长具有更强的抑制作用,且在其他实体瘤药效...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.